ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Clinical Nurse Specialist, Psychiatric/Mental Health, Community

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,015Medicare Part D Prescriptions Filled, Including Refills
$1.97M Total Retail Price of All Prescriptions
462 Patients Receiving at Least One Drug in Part D
10%Patients 65 Years and Older
92% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
SERTRALINE HCL 626 72
OLANZAPINE 579 94
RISPERIDONE 497 27
BENZTROPINE MESYLATE 480 22 R
CLOZAPINE 449 0
BUPROPION XL 398 38
FLUOXETINE HCL 391 20
ZIPRASIDONE HCL 385 36
QUETIAPINE FUMARATE 378 50
TRAZODONE HCL 365 71
PAROXETINE HCL 348 83
ABILIFY 307 22
MIRTAZAPINE 303 39
VENLAFAXINE HCL ER 281 87
INVEGA SUSTENNA 214 15
INVEGA 195 0
TRIHEXYPHENIDYL HCL 191 26 R
CYMBALTA 191 0
LATUDA 181 0
OXCARBAZEPINE 169 0
LITHIUM CARBONATE 164 0
CITALOPRAM HBR 149 0
SEROQUEL XR 144 0
SEROQUEL 141 18
GEODON 138 14
RISPERDAL CONSTA 135 0
ESCITALOPRAM OXALATE 120 0
BUPROPION HCL SR 117 0
DIVALPROEX SODIUM ER 116 0
GABAPENTIN 112 13
OLANZAPINE ODT 104 0
BUSPIRONE HCL 102 31
FANAPT 98 0
LAMOTRIGINE 96 0
PROPRANOLOL HCL 92 0
DIVALPROEX SODIUM 92 25
AMANTADINE 90 20
HYDROXYZINE PAMOATE 88 0 R
ZOLPIDEM TARTRATE 85 0
CYPROHEPTADINE HCL 65 13 R
HALOPERIDOL 53 0
HYDROXYZINE HCL 51 0 R
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.